These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15149645)

  • 1. Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.
    Wendt MD; Geyer A; McClellan WJ; Rockway TW; Weitzberg M; Zhao X; Mantei R; Stewart K; Nienaber V; Klinghofer V; Giranda VL
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3063-8. PubMed ID: 15149645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.
    Wendt MD; Rockway TW; Geyer A; McClellan W; Weitzberg M; Zhao X; Mantei R; Nienaber VL; Stewart K; Klinghofer V; Giranda VL
    J Med Chem; 2004 Jan; 47(2):303-24. PubMed ID: 14711304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.
    Bruncko M; McClellan WJ; Wendt MD; Sauer DR; Geyer A; Dalton CR; Kaminski MA; Weitzberg M; Gong J; Dellaria JF; Mantei R; Zhao X; Nienaber VL; Stewart K; Klinghofer V; Bouska J; Rockway TW; Giranda VL
    Bioorg Med Chem Lett; 2005 Jan; 15(1):93-8. PubMed ID: 15582418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
    West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines.
    Barber CG; Dickinson RP; Fish PV
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3227-30. PubMed ID: 15149680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species specificity of amidine-based urokinase inhibitors.
    Klinghofer V; Stewart K; McGonigal T; Smith R; Sarthy A; Nienaber V; Butler C; Dorwin S; Richardson P; Weitzberg M; Wendt M; Rockway T; Zhao X; Hulkower KI; Giranda VL
    Biochemistry; 2001 Aug; 40(31):9125-31. PubMed ID: 11478879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
    Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
    J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
    Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
    Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
    Spencer JR; McGee D; Allen D; Katz BA; Luong C; Sendzik M; Squires N; Mackman RL
    Bioorg Med Chem Lett; 2002 Aug; 12(15):2023-6. PubMed ID: 12113833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification of urokinase by a beta-naphthamidine affinity column.
    Astedt B; Holmberg L; Wagner G; Richter P; Ploug J
    Thromb Haemost; 1979 Oct; 42(3):924-8. PubMed ID: 505406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
    Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
    J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA).
    Venkatraj M; Messagie J; Joossens J; Lambeir AM; Haemers A; Van der Veken P; Augustyns K
    Bioorg Med Chem; 2012 Feb; 20(4):1557-68. PubMed ID: 22285569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator.
    Crippa MP
    Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: the influence of the ester group on their biological activity.
    Sieńczyk M; Oleksyszyn J
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2886-90. PubMed ID: 16546384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Explaining urokinase type plasminogen activator inhibition by amino-5-hydroxybenzimidazole and two naphthamidine-based compounds through quantum biochemistry.
    Solis-Calero C; Zanatta G; Pessoa CDÓ; Carvalho HF; Freire VN
    Phys Chem Chem Phys; 2018 Sep; 20(35):22818-22830. PubMed ID: 30151512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite.
    Nienaber VL; Davidson D; Edalji R; Giranda VL; Klinghofer V; Henkin J; Magdalinos P; Mantei R; Merrick S; Severin JM; Smith RA; Stewart K; Walter K; Wang J; Wendt M; Weitzberg M; Zhao X; Rockway T
    Structure; 2000 May; 8(5):553-63. PubMed ID: 10801494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors.
    Rudolph MJ; Illig CR; Subasinghe NL; Wilson KJ; Hoffman JB; Randle T; Green D; Molloy CJ; Soll RM; Lewandowski F; Zhang M; Bone R; Spurlino JC; Deckman IC; Manthey C; Sharp C; Maguire D; Grasberger BL; DesJarlais RL; Zhou Z
    Bioorg Med Chem Lett; 2002 Feb; 12(3):491-5. PubMed ID: 11814826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
    Andersen LM; Wind T; Hansen HD; Andreasen PA
    Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.